Showing results (81-90 of 158) with videos related to

Sort By:
Pageof 16
Cancer Chemotherapy and Pharmacology|June 29, 2011
Imatinib mesylate in thymic epithelial malignanciesGiovannella Palmieri, Mirella Marino, Carlo Buonerba, et al.
Journal of Personalized Medicine|April 3, 2021
Liquid Biopsy Biomarkers in Urine: A Route towards Molecular Diagnosis and Personalized Medicine of Bladder CancerMatteo Ferro, Evelina La Civita, Antonietta Liotti, et al.
Oncology and Therapy|February 28, 2024
Unraveling the Dietary Puzzle: Exploring the Influence of Diet, Nutraceuticals, and Supplements on Bladder Cancer Risk, Outcomes, and Immunotherapy Efficacy: Insights from the BLOSSOM Study and BeyondCarlo Buonerba, Concetta Ingenito, Rossella Di Trolio, et al.
Nutrients|October 16, 2024
The Impact of Flavonoid Supplementation on Serum Oxidative Stress Levels Measured via D-ROMs Test in the General Population: The PREVES-FLAVON Retrospective Observational StudyGiuseppe Di Lorenzo, Antonio Verde, Luca Scafuri, et al.
Oncology and Therapy|June 28, 2024
Exploring a Novel Approach to Spare Classic Chemotherapy in HER2-Low, ER-Positive Breast Cancer Based on Trastuzumab Deruxtecan Combined with Endocrine TherapyLuca Scafuri, Carlo Buonerba, Vincenzo Di Lauro, et al.
European Urology|August 30, 2011
Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 studyGiuseppe Di Lorenzo, Piera Federico, Carlo Buonerba, et al.
Future Oncology (London, England)|December 5, 2014
Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trialGiovannella Palmieri, Carlo Buonerba, Margaret Ottaviano, et al.
Future Oncology (London, England)|July 24, 2014
Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patientsCarlo Buonerba, Piera Federico, Davide Bosso, et al.
Frontiers in Public Health|April 21, 2022
Assessment of Saliva Specimens' Reliability for COVID-19 SurveillanceBiancamaria Pierri, Maria Tafuro, Maria Concetta Cuomo, et al.
European Urology|October 2, 2010
Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinomaGiuseppe Di Lorenzo, Carlo Buonerba, Piera Federico, et al.
Pageof 16